SCHEMBL1053952

SCHEMBL1053952

NC(=O)N1CCCC1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27832717 0.98 POLB (0.36)
SCHEMBL19025613 0.93 GAA (0.35)
SCHEMBL16829985 0.86
SCHEMBL16096027 0.79
SCHEMBL1053950 0.77
SCHEMBL5017013 0.77
SCHEMBL30489287 0.74
SCHEMBL7008319 0.74
SCHEMBL4028301 0.74 HPGD (0.37)
SCHEMBL3109587 0.73 GAA (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510491-A Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides 阿尔维纳斯运营股份有限公司 2024-02-06 CN disclosed
US-20220324863-A1 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2022-10-13 US disclosed
US-11384078-B2 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2022-07-12 US disclosed
EP-3630771-A1 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES Novartis AG (CH) 2020-04-08 EP disclosed
WO-2018220531-A1 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2018-12-06 WO disclosed
EP-3340981-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2018-07-04 EP disclosed
WO-2017035353-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-02 WO disclosed
US-8063045-B2 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity SANOFI-AVENTIS (FR) 2011-11-22 US disclosed
EP-2368880-A1 6-(Heterocycle-Substituted Benzyl)-4-Oxoquinoline Compound and Use of the Same as HIV Integrase Inhibitor Japan Tobacco, Inc. (JP) 2011-09-28 EP disclosed
US-7872004-B2 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2011-01-18 US disclosed
US-20100210838-A1 FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY SANOFI-AVENTIS (FR) 2010-08-19 US disclosed
US-7655663-B2 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity SANOFI-AVENTIS (FR) 2010-02-02 US disclosed
EP-1487807-B1 Cyano-pyrrolidines as DPP-IV inhibitors SANOFI AVENTIS (FR) 2009-09-16 EP disclosed
EP-2033954-A1 6-(HETEROCYCLE-SUBSTITUTED BENZYL)-4-OXOQUINOLINE COMPOUND AND USE OF THE SAME AS HIV INTEGRASE INHIBITOR Japan Tobacco, Inc. (JP) 2009-03-11 EP disclosed
US-20080207618-A1 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor JAPAN TOBACCO INC. (JP) 2008-08-28 US disclosed
US-20080161310-A1 FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY SANOFI-AVENTIS (FR) 2008-07-03 US disclosed
US-7348327-B2 Compounds SANOFI-AVENTIS (FR) 2008-03-25 US disclosed
US-20050130981-A1 Compounds SANOFI-AVENTIS (FR) 2005-06-16 US disclosed
EP-1487807-A2 NEW COMPOUNDS Sanofi-Aventis (FR) 2004-12-22 EP disclosed
WO-2003074500-A2 N-AMINOACETYL-PYRROLIDINE-2-CARBONITRILES AND THEIR USE AS DDP-IV INHIBITORS SANOFI-AVENTIS (FR) 2003-09-12 WO disclosed